Haemorrhage prophylaxis Trials in Disease

Study on Tranexamic Acid Oral Solution for Preventing Bleeding in Patients on Blood Thinners Undergoing Tooth Extraction

This clinical trial focuses on preventing bleeding complications in patients who take blood thinners and need dental extractions. The study is being conducted across multiple countries including Croatia, Spain, Romania, and Hungary.

Main inclusion criteria: Participants must be at least 18 years old with a body mass index between 18.5 and 35, weighing at least 50 kg. They need to have been taking direct oral anticoagulants or vitamin K antagonists regularly for at least 3 months. For those on vitamin K antagonists, their International Normalized Ratio should be between 2.0 and 3.5. Male participants must have a hemoglobin level of at least 12.0 g/dL, while females need at least 11.0 g/dL. Women of childbearing age must have a negative pregnancy test and agree to use effective birth control. Participants must be scheduled for one or more tooth extractions and willing to avoid alcohol during the study.

Main exclusion criteria: The trial excludes patients who are not taking direct oral anticoagulants or vitamin K antagonists, those not undergoing tooth extraction, patients not at risk of significant bleeding, and individuals outside the specified age range or clinical trial groups.

Trial focus: The main goal is to determine whether Tranexamic Acid Oral Solution 5% can effectively reduce clinically important bleeding after tooth extractions compared to a placebo. This double-blind study will monitor participants for bleeding episodes following their dental procedures for up to seven days. Researchers will also assess how acceptable the medication is for patients to take as directed.

Investigational drug: Tranexamic Acid Oral Solution 5% is the medication being tested. It works by helping blood clot more effectively, preventing excessive bleeding. This liquid medication is taken by mouth and aims to reduce bleeding risk in patients whose blood-thinning medications make them more prone to bleeding complications.

Study on Heparin and Nadroparin Calcium for Patients Undergoing ECMO Treatment to Reduce Bleeding Risks

This trial investigates blood-thinning medications for patients receiving extracorporeal membrane oxygenation, a life-support technique for severe heart and lung problems. The study is taking place in the Netherlands.

Main inclusion criteria: Participants must be adults aged 18 years or older who are receiving ECMO treatment at the intensive care unit of a participating center. Both men and women can participate, provided they are not part of a vulnerable population that requires special protection.

Main exclusion criteria: Patients receiving ECMO treatment solely to support a medical procedure, such as a high-risk heart procedure or during surgery, cannot participate in the study.

Trial focus: The study aims to find out whether using lower doses of blood thinners can reduce major bleeding complications without increasing the risk of blood clots in ECMO patients. Researchers will compare the effects of these medications on bleeding, blood clots, and overall survival. Participants will be monitored for up to six months to track outcomes including the need for blood transfusions, quality of life, and complications related to blood clots. The trial is expected to conclude by March 2025.

Investigational drugs: The study is testing two medications: Unfractionated Heparin, given through a vein, and Nadroparin Calcium (Low Molecular Weight Heparin), given as an injection under the skin. Both medications prevent blood clots by inhibiting certain factors in the blood clotting process. The trial will determine if using these medications with reduced anticoagulation targets can improve safety and effectiveness of ECMO therapy.

Summary

These two clinical trials address bleeding prevention in distinctly different medical situations. The first trial focuses on a common dental procedure in patients taking blood thinners across four European countries, while the second concentrates on critically ill patients requiring life support in the Netherlands. Both studies share the goal of finding the optimal balance between preventing dangerous blood clots and avoiding serious bleeding complications. The tranexamic acid trial represents a Phase 3 investigation, suggesting this approach may be closer to potential clinical application. These trials demonstrate ongoing efforts to improve safety for patients requiring anticoagulation therapy in various medical contexts.